Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen) in advanced malignancies.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
Works matching IS 01676997 AND DT 2010 AND VI 28 AND IP 4
Results: 22
1
2
MER1, a novel organic arsenic derivative, has potent PML-RAR[alpha]- independent cytotoxic activity against leukemia cells.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
3
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
4
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 523, doi. 10.1007/s10637-009-9280-2
- By:
- Publication type:
- Article
5
Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 472, doi. 10.1007/s10637-009-9278-9
- By:
- Publication type:
- Article
6
Synthesis and identification of a new class of (S)-2,6-diamino-4,5,6,7-tetrahydrobenzo[d]thiazole derivatives as potent antileukemic agents.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 454, doi. 10.1007/s10637-009-9276-y
- By:
- Publication type:
- Article
7
Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 493, doi. 10.1007/s10637-010-9424-4
- By:
- Publication type:
- Article
8
The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 392, doi. 10.1007/s10637-009-9263-3
- By:
- Publication type:
- Article
9
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
- Published in:
- 2010
- By:
- Publication type:
- Report
10
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 502, doi. 10.1007/s10637-009-9258-0
- By:
- Publication type:
- Article
11
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 509, doi. 10.1007/s10637-009-9264-2
- By:
- Publication type:
- Article
12
Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 381, doi. 10.1007/s10637-009-9255-3
- By:
- Publication type:
- Article
13
Evaluation Of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 363, doi. 10.1007/s10637-009-9256-2
- By:
- Publication type:
- Article
14
The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 445, doi. 10.1007/s10637-009-9270-4
- By:
- Publication type:
- Article
15
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 413, doi. 10.1007/s10637-009-9269-x
- By:
- Publication type:
- Article
16
Cytotoxic activities of new iron(III) and nickel(II) chelates of some S-methyl-thiosemicarbazones on K562 and ECV304 cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 421, doi. 10.1007/s10637-009-9272-2
- By:
- Publication type:
- Article
17
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 433, doi. 10.1007/s10637-009-9266-0
- By:
- Publication type:
- Article
18
Reversible cardiogenic shock following 5-Fluorouracil infusion.
- Published in:
- 2010
- By:
- Publication type:
- Report
19
MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 402, doi. 10.1007/s10637-009-9267-z
- By:
- Publication type:
- Article
20
Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss mice.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 466, doi. 10.1007/s10637-009-9274-0
- By:
- Publication type:
- Article
21
Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 482, doi. 10.1007/s10637-009-9277-x
- By:
- Publication type:
- Article
22
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 4, p. 516, doi. 10.1007/s10637-009-9283-z
- By:
- Publication type:
- Article